Ribi Immunochem
Executive Summary
Will expand Phase II trial of melanoma tumor vaccine derived from cultured tumor cell lines and the firm's immunostimulant Detox from 70 patients to 270 patients at five new study sites. FDA clearance of the firm's Hamilton, Montana facility for the production of its cancer vaccine made the additional studies possible. The vaccine had been produced in limited amounts at the University of Southern California.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.